These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10698349)

  • 1. Complement activation and atherosclerosis.
    Niculescu F; Rus H
    Mol Immunol; 1999; 36(13-14):949-55. PubMed ID: 10698349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of complement activation in atherosclerosis.
    Niculescu F; Rus H
    Immunol Res; 2004; 30(1):73-80. PubMed ID: 15258311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells.
    Niculescu F; Soane L; Badea T; Shin M; Rus H
    Immunopharmacology; 1999 May; 42(1-3):187-93. PubMed ID: 10408379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase.
    Niculescu F; Badea T; Rus H
    Atherosclerosis; 1999 Jan; 142(1):47-56. PubMed ID: 9920505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells.
    Niculescu F; Rus H
    Immunol Res; 2001; 24(2):191-9. PubMed ID: 11594456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
    Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
    Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway.
    Rus H; Niculescu F; Badea T; Shin ML
    Immunopharmacology; 1997 Dec; 38(1-2):177-87. PubMed ID: 9476129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent.
    Niculescu F; Rus H; van Biesen T; Shin ML
    J Immunol; 1997 May; 158(9):4405-12. PubMed ID: 9127005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-localization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls.
    Rus HG; Niculescu F; Vlaicu R
    Immunol Lett; 1988 Sep; 19(1):27-32. PubMed ID: 3192278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits.
    Seifert PS; Hugo F; Hansson GK; Bhakdi S
    Lab Invest; 1989 Jun; 60(6):747-54. PubMed ID: 2659887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1.
    Viedt C; Hänsch GM; Brandes RP; Kübler W; Kreuzer J
    FASEB J; 2000 Dec; 14(15):2370-2. PubMed ID: 11024008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of complement activation in atherogenesis: the first 40 years.
    Vlaicu SI; Tatomir A; Rus V; Mekala AP; Mircea PA; Niculescu F; Rus H
    Immunol Res; 2016 Feb; 64(1):1-13. PubMed ID: 26091721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes.
    Pippin JW; Durvasula R; Petermann A; Hiromura K; Couser WG; Shankland SJ
    J Clin Invest; 2003 Mar; 111(6):877-85. PubMed ID: 12639994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.
    Vlaicu R; Niculescu F; Rus HG; Cristea A
    Atherosclerosis; 1985 Nov; 57(2-3):163-77. PubMed ID: 3910058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RGC-32' dual role in smooth muscle cells and atherogenesis.
    Vlaicu SI; Tatomir A; Fosbrink M; Nguyen V; Boodhoo D; Cudrici C; Badea TC; Rus V; Rus H
    Clin Immunol; 2022 May; 238():109020. PubMed ID: 35462050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of C5b-9 and RGC-32 in Cancer.
    Vlaicu SI; Tatomir A; Rus V; Rus H
    Front Immunol; 2019; 10():1054. PubMed ID: 31156630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane attack by complement: the assembly and biology of terminal complement complexes.
    Tegla CA; Cudrici C; Patel S; Trippe R; Rus V; Niculescu F; Rus H
    Immunol Res; 2011 Oct; 51(1):45-60. PubMed ID: 21850539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of apoptosis signal-regulating kinase 1 in complement-mediated glomerular epithelial cell injury.
    Ren G; Huynh C; Bijian K; Cybulsky AV
    Mol Immunol; 2008 Apr; 45(8):2236-46. PubMed ID: 18178252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
    Gancz D; Donin N; Fishelson Z
    Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+.
    Carney DF; Hammer CH; Shin ML
    J Immunol; 1986 Jul; 137(1):263-70. PubMed ID: 3711667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.